Alexion Can't Halt Amgen, Samsung Soliris Biosimilars In UK
A London court has cleared Samsung and Amgen's path to launching biosimilar versions of the blood disease drug Soliris, ruling on Tuesday that they will not infringe an AstraZeneca subsidiary's patent....To view the full article, register now.
Already a subscriber? Click here to view full article